(IN BRIEF) Simon Linder, a PhD candidate, conducted multi-omics research to understand how tumor cells adapt to hormonal therapies in prostate cancer. Prostate cancer is hormone-dependent, and although hormonal therapy is initially effective, cancer cells eventually become resistant to it. By analyzing biochemical data through a multi-omics approach, Linder discovered that a protein involved in the circadian rhythm plays a role in driving resistance to hormonal therapy. Further analysis confirmed this finding, and blocking the production of this protein re-sensitized resistant cells to therapy. These findings open up possibilities for developing new therapeutic approaches for prostate cancer patients.
(PRESS RELEASE) EINDHOVEN, 4-Jul-2023 — /EuropaWire/ — Prostate cancer is a hormone-dependent type of cancer, which means that the cancer cells develop under the influence of male sex hormones. Good results can be achieved with hormonal therapy, but the big problem with this is that cancer cells can adapt to it, causing the tumors to become resistant to this treatment after a while. PhD candidate Simon Linder, who defended his thesis on June 30, conducted a broad multi-omics analysis to see exactly how cancer cells adapt. This led him to discover which protein – surprisingly – plays an important role in this process.
The German-born PhD candidate conducted his doctoral research under the supervision of Wilbert Zwart, a full professor at the TU/e Department of Biomedical Engineering and the leader of the Hormone-associated Cancer research group at the Netherlands Cancer Institute (NKI). “In this group we focus on hormone-dependent cancers, primarily breast cancer and prostate cancer, but in recent years we’ve been finding that hormones also play a role in some other types of cancers, such as lung cancer,” Linder says. Conducting his doctoral research within this research group, his own particular area of study was prostate cancer. This is a very prevalent hormone-driven cancer; in the Netherlands alone about 12,000 men are diagnosed with the disease every year, and more than 3,000 die. “So there is still much we can do to improve the therapy available to these patients.”
Resistance
“If the disease is contained within the organ, we can remove the prostate surgically – with a prostatectomy as it is called – or we can give radiotherapy,” he continues. “Around 70% of patients are cured by this intervention, which is great. But in around 30% of patients the disease returns.” These patients are usually treated with hormonal therapy. This treatment aims to inhibit the body’s production of male sex hormones, called androgens, which fuel prostate cancer growth.
“In prostate cancer cells, hormones activate a certain pathway to cell growth and survival. If you either block the biosynthesis (assembly of biomolecules, ed.) of these hormones or inhibit the molecule that needs the hormones to activate the pathway, you can successfully inhibit this process”, Linder explains. “These therapies are very effective at first, but the big problem is that the tumors become resistant to them pretty soon.”
Smart cancer cells
“In a way, cancer cells are very smart,” he continues. “If you block the pathway they usually take and depend on, after a while they find byways that enable them eventually to accomplish the same goal. By which I mean they activate something else that can carry and drive the disease.” Unfortunately it is inevitable that sooner or later these tumors will become resistant. And it is this resistance that poses the biggest challenge in treating both prostate cancer and other hormone-driven diseases.
The important question is this: how do these tumor cells adapt to hormonal therapies? If we are to prevent cancer cells from developing resistance, a more fundamental understanding of these processes is required. “We need to outsmart them,” Linder says. During his research at the NKI, in association with the Antoni van Leeuwenhoek clinic, he focused on patients with primary, localized prostate cancer in order to gain greater insight into the behavior of cancer cells. “We gave these patients hormonal therapy three months before they had surgery. Biopsies were taken before and after the hormonal therapy which enabled us to address an important question: what does hormone therapy do to cancer cells?”
The bigger picture
In this work, Linder used what is known as the multi-omics approach. This involves analyzing a large amount of biochemical data to gain new and deeper insights. Omics refers to different fields of molecular biology that end in ‘-omics’, such as genomics (the study of DNA), transcriptomics (the study of RNA) or proteomics (the study of proteins). “With multi-omics, we’re looking at all the molecules of the same type, let’s say DNA, in the same sample,” he explains. “So we don’t look at only one DNA sequence, but at all of them. And we do the very same thing for the RNA – a kind of recipe for how to make the protein later on – and for the proteins themselves.”
“With this broad multi-omic analysis, you have a lot of small parts that you need to put together to form the bigger picture. It’s like a jigsaw puzzle with lots of little pieces that add up to something much bigger.” Linder analyzed all these factors within the samples taken before and after hormonal treatment to see what was different and to understand what was driving the resistance. The ultimate goal would be to find ways to block this and prevent resistance, or even to re-sensitize cells that have become resistant to the therapy.
Surprising discovery
After extensive analysis, he discovered that a protein that normally plays a role in a very general physiological process had suddenly taken on a whole new role in driving this resistance. “This protein normally plays a role in the circadian rhythm, meaning the day and night rhythm that is present in every cell of our body and causes us to be more awake in the morning and sleepier at night,” he explains. “The interesting thing is that the circadian rhythm is often lost in cancer cells and suddenly this protein was given a new role in prostate cancer. We were all very surprised by this, because it has never been described in prostate cancer before, especially not in driving resistance to hormonal therapy.”
Linder decided to delve deeper into this and then conducted more analysis to confirm this surprising discovery. No longer on patient samples, but in vitro, using a disease model that he grew in the lab to see how the cells respond to therapy. “This way we can both model therapies and also try to better understand the biology of these tumors,” he explains. This analysis work showed that resistant cells become sensitive to therapy again when you prevent the production of this specific circadian rhythm protein, confirming the role of this protein in the resistance mechanism. “If you block the main pathway, the cancer cells find a workaround to achieve their goal. But now if we also block this bypass option, the cancer cells can’t do anything and eventually they die.”
Outside the box
“It was very cool to see that these initially very broad analysis with lots of patient samples and lots of data eventually led to one driver that could be validated in these models,” Linder says. Ultimately, he believes these findings could lead to a new therapeutic approach for patients with prostate cancer. “Not today, but in the future,” he adds, since specific drugs that target this circadian rhythm protein first need to be developed.
“From this research project I learned that you should never rule out anything in advance,” he continues. “If you had asked me beforehand what drives resistance in prostate cancer, the circadian rhythm would never have been something I’d have put my money on, just because it’s such a normal physiological pathway. But now we know that cancer cells can hijack even proteins that normally play a role in a very normal process and use them to achieve their ultimate goal, which is to grow and survive. So if we want to advance therapies and improve patients’ lives, we need to do more thinking outside the box.”
This article was written by Cursor.
Media Contact:
Barry van der Meer
Head of Department
Tel: +31 40 247 4061
Email: b.v.d.meer@tue.nl
Source: TU/e
MORE ON TU/E, ETC.:
- Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas
- Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze
- ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności
- Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity
- Digi Communications NV announces the release of H1 2024 Financial Results
- Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary
- Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results
- Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal
- Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.
- Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain
- SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022
- Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report
- Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall
- SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests
- WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds
- Museum of Unrest: a new space for activism, art and design
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group
- Digi Communications N.V. announces the agreements concluded by Digi Romania (formerly named RCS & RDS S.A.), the Romanian subsidiary of the Company
- Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026
- Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024
- Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group
- Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report
- Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results
- Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024
- Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report
- Digi Communications N.V. announces the availability of the 2023 Annual Report
- International Airlines Group adopts Airline Economics by Skailark ↗️
- BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility
- Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
- BevZero South Africa Achieves FSSC 22000 Food Safety Certification
- Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
- Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
- driveMybox continues its international expansion: Hungary as a new strategic location
- Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
- Digi Communications NV announces the release of the 2023 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
- Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
- Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
- Digi Communications N.V. Announces the release of the Financial Calendar for 2024
- Customer Data Platform Industry Attracts New Participants: CDP Institute Report
- eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
- BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
- Digi Communications N.V. announces share transaction made by a Non-Executive Director of the Company with class B shares
- Digi Spain Telecom, the subsidiary of Digi Communications NV in Spain, has concluded a spectrum transfer agreement for the purchase of spectrum licenses
- Эксперт по торговле акциями Сергей Левин запускает онлайн-мастер-класс по торговле сырьевыми товарами и хеджированию
- Digi Communications N.V. announces the conclusion by Company’s Portuguese subsidiary of a framework agreement for spectrum usage rights
- North Texas Couple Completes Dream Purchase of Ouray’s Iconic Beaumont Hotel
- Предприниматель и филантроп Михаил Пелег подчеркнул важность саммита ООН по Целям устойчивого развития 2023 года в Нью-Йорке
- Digi Communications NV announces the release of the Q3 2023 Financial Results
- IQ Biozoom Innovates Non-Invasive Self-Testing, Empowering People to Self-Monitor with Laboratory Precision at Home
- BevZero Introduces Energy Saving Tank Insulation System to Europe under name “BevClad”
- Motorvision Group reduces localization costs using AI dubbing thanks to partnering with Dubformer
- Digi Communications NV Announces Investors Call for the Q3 2023 Financial Results
- Jifiti Granted Electronic Money Institution (EMI) License in Europe
- Предприниматель Михаил Пелег выступил в защиту образования и грамотности на мероприятии ЮНЕСКО, посвящённом Международному дню грамотности
- VRG Components Welcomes New Austrian Independent Agent
- Digi Communications N.V. announces that Digi Spain Telecom S.L.U., its subsidiary in Spain, and abrdn plc have completed the first investment within the transaction having as subject matter the financing of the roll out of a Fibre-to-the-Home (“FTTH”) network in Andalusia, Spain
- Продюсер Михаил Пелег, как сообщается, работает над новым сериалом с участием крупной голливудской актрисы
- Double digit growth in global hospitality industry for Q4 2023
- ITC Deploys Traffic Management Solution in Peachtree Corners, Launches into United States Market
- Cyviz onthult nieuwe TEMPEST dynamische controlekamer in Benelux, Nederland
- EU-Funded CommuniCity Launches its Second Open Call
- Astrologia pode dar pistas sobre a separação de Sophie Turner e Joe Jonas
- La astrología puede señalar las razones de la separación de Sophie Turner y Joe Jonas
- Empowering Europe against infectious diseases: innovative framework to tackle climate-driven health risks
- Montachem International Enters Compostable Materials Market with Seaweed Resins Company Loliware
- Digi Communications N.V. announces that its Belgian affiliated companies are moving ahead with their operations
- Digi Communications N.V. announces the exercise of conditional share options by an executive director of the Company, for the year 2022, as approved by the Company’s Ordinary General Shareholders’ Meeting from 18 May 2021
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2022 financial year
- Digi Communications N.V. announces the availability of the 2022 Annual Report
- Digi Communications N.V. announces the general shareholders’ meeting resolutions from 18 August 2023 approving amongst others, the 2022 Annual Accounts
- Русские эмигранты усиливают призывы «Я хочу, чтобы вы жили» через искусство
- BevZero Introduces State-of-the-Art Mobile Flash Pasteurization Unit to Enhance Non-Alcoholic Beverage Stability at South Africa Facility
- Russian Emigrés Amplify Pleas of “I Want You to Live” through Art
- Digi Communications NV announces the release of H1 2023 Financial Results
- Digi Communications NV Announces Investors Call for the H1 2023 Financial Results
- Digi Communications N.V. announces the convocation of the Company’s general shareholders meeting for 18 August 2023 for the approval of, among others, the 2022 Annual Report
- “Art Is Our Weapon”: Artists in Exile Deploy Their Talents in Support of Peace, Justice for Ukraine
- Digi Communications N.V. announces the availability of the 2022 Annual Financial Report
- “AmsEindShuttle” nuevo servicio de transporte que conecta el aeropuerto de Eindhoven y Ámsterdam
- Un nuovo servizio navetta “AmsEindShuttle” collega l’aeroporto di Eindhoven ad Amsterdam
- Digi Communications N.V. announces the conclusion of an amendment agreement to the Facility Agreement dated 26 July 2021, by the Company’s Spanish subsidiary
- Digi Communications N.V. announces an amendment of the Company’s 2023 financial calendar
- iGulu F1: Brewing Evolution Unleashed
- Почему интерактивная «Карта мира» собрала ключевые антивоенные сообщества россиян по всему миру и становится для них важнейшим инструментом
- Hajj Minister meets EU ambassadors to Saudi Arabia
- Online Organizing Platform “Map of Peace” Emerges as Key Tool for Diaspora Activists
- Digi Communications N.V. announces that conditional stock options were granted to executive directors of the Company based on the general shareholders’ meeting approval from 18 May 2021
- Digi Communications N.V. announces the release of the Q1 2023 financial results
- AMBROSIA – A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE
- Digi Communications NV announces Investors Call for the Q1 2023 Financial Results presentation
- Digi Communications N.V. announces the amendment of the Company’s 2023 financial calendar
- Digi Communications N.V. announces the conclusion of two Facilities Agreements by the Company’s Romanian subsidiary
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by the Company’s Romanian subsidiary
- Patients as Partners Europe Returns to London and Announces Agenda Highlights
- GRETE PROJECT RESULTS PRESENTED TO TEXTILE INDUSTRY STAKEHOLDERS AT INTERNATIONAL CELLULOSE FIBRES CONFERENCE
- Digi Communications N.V. announces Digi Spain Telecom S.L.U., its subsidiary in Spain, entered into an investment agreement with abrdn to finance the roll out of a Fibre-to-the-Home (FTTH) network in Andalusia, Spain
- XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)
- Franklin Junction Expands Host Kitchen® Network To Europe with Digital Food Hall Pioneer Casper
- Unihertz a dévoilé un nouveau smartphone distinctif, Luna, au MWC 2023 de Barcelone
- Unihertz Brachte ein Neues, Markantes Smartphone, Luna, auf dem MWC 2023 in Barcelona
- Editor's pick archive....